174 related articles for article (PubMed ID: 8666365)
1. Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma.
Felix A; El-Naggar AK; Press MF; Ordonez NG; Fonseca I; Tucker SL; Luna MA; Batsakis JG
Hum Pathol; 1996 Jun; 27(6):561-6. PubMed ID: 8666365
[TBL] [Abstract][Full Text] [Related]
2. Polymorphous low-grade adenocarcinoma: flow cytometric, p53, and PCNA analysis.
Kelsch RD; Bhuiya T; Fuchs A; Gentile P; Kahn MA; Fantasia JE
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 1997 Oct; 84(4):391-9. PubMed ID: 9347503
[TBL] [Abstract][Full Text] [Related]
3. Salivary duct carcinoma: clinicopathological and immunohistochemical studies.
Martinez-Barba E; Cortes-Guardiola JA; Minguela-Puras A; Torroba-Caron A; Mendez-Trujillo S; Bermejo-Lopez J
J Craniomaxillofac Surg; 1997 Dec; 25(6):328-34. PubMed ID: 9504310
[TBL] [Abstract][Full Text] [Related]
4. [Mucoepidermoid carcinoma of salivary glands: the prognostic value of tumoral markers].
Hoyek-Gebeily J; Nehmé E; Aftimos G; Sader-Ghorra C; Sargi Z; Haddad A
Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):482-8. PubMed ID: 17761202
[TBL] [Abstract][Full Text] [Related]
5. Prognostic role of apoptotic, Bcl-2, c-erbB-2 and p53 tumor markers in salivary gland malignancies.
Nagler RM; Kerner H; Ben-Eliezer S; Minkov I; Ben-Itzhak O
Oncology; 2003; 64(4):389-98. PubMed ID: 12759537
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of malignant grade of salivary gland tumors: studies by cytofluorometric nuclear DNA analysis, histochemistry for nucleolar organizer regions and immunohistochemistry for p53.
Ishii K; Nakajima T
Pathol Int; 1994 Apr; 44(4):287-96. PubMed ID: 8044296
[TBL] [Abstract][Full Text] [Related]
7. Molecular and biomarker analyses of salivary duct carcinomas: comparison with mammary duct carcinoma.
Hoang MP; Callender DL; Sola Gallego JJ; Huang Z; Sneige N; Luna MA; Batsakis JG; El-Naggar AK
Int J Oncol; 2001 Oct; 19(4):865-71. PubMed ID: 11562768
[TBL] [Abstract][Full Text] [Related]
8. Objective biologic parameters and their clinical relevance in assessing salivary gland neoplasms.
Pinto AE; Fonseca I; Martins C; Soares J
Adv Anat Pathol; 2000 Sep; 7(5):294-306. PubMed ID: 10976908
[TBL] [Abstract][Full Text] [Related]
9. Epithelial-myoepithelial carcinoma of salivary glands. A clinicopathologic, DNA flow cytometric, and immunohistochemical study of Ki-67 and HER-2/neu oncogene.
Cho KJ; el-Naggar AK; Ordonez NG; Luna MA; Austin J; Batsakis JG
Am J Clin Pathol; 1995 Apr; 103(4):432-7. PubMed ID: 7726139
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathological study of salivary duct carcinoma].
Shimizu A; Yamane M; Ito H; Araki S; Yoshida T; Suzuki M
Nihon Jibiinkoka Gakkai Kaiho; 2002 Jun; 105(6):727-31. PubMed ID: 12138700
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder.
Shiina H; Igawa M; Nagami H; Yagi H; Urakami S; Yoneda T; Shirakawa H; Ishibe T; Kawanishi M
Cancer; 1996 Oct; 78(8):1762-74. PubMed ID: 8859190
[TBL] [Abstract][Full Text] [Related]
12. Carcinoma ex pleomorphic adenoma: pathologic analysis of 73 cases.
Lewis JE; Olsen KD; Sebo TJ
Hum Pathol; 2001 Jun; 32(6):596-604. PubMed ID: 11431714
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness.
Sugano S; Mukai K; Tsuda H; Hirohashi S; Furuya S; Shimosato Y; Ebihara S; Takeyama I
Laryngoscope; 1992 Aug; 102(8):923-7. PubMed ID: 1353853
[TBL] [Abstract][Full Text] [Related]
14. Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance.
Nagao T; Gaffey TA; Visscher DW; Kay PA; Minato H; Serizawa H; Lewis JE
Am J Surg Pathol; 2004 Mar; 28(3):319-26. PubMed ID: 15104294
[TBL] [Abstract][Full Text] [Related]
15. The implications of TrkA and MET aberrations in de novo salivary duct carcinoma.
Ryu HJ; Koh YW; Yoon SO
Hum Pathol; 2018 Nov; 81():18-25. PubMed ID: 29753009
[TBL] [Abstract][Full Text] [Related]
16. [Relationship between expressions of p53, c-erbB2 genes, proliferating cell nuclear antigen and prognosis of patients with ovarian epithelial carcinoma].
Li JD; Li MD; Li YF; Huang X; Liu JH; Liu FY; Zhang CQ
Ai Zheng; 2002 Mar; 21(3):292-6. PubMed ID: 12451998
[TBL] [Abstract][Full Text] [Related]
17. Acinic cell carcinoma of minor salivary glands: a clinical and immunohistochemical study.
Triantafillidou K; Iordanidis F; Psomaderis K; Kalimeras E
J Oral Maxillofac Surg; 2010 Oct; 68(10):2489-96. PubMed ID: 20678839
[TBL] [Abstract][Full Text] [Related]
18. Fibrosarcoma versus fibromatoses and cellular nodular fasciitis. A comparative study of their proliferative activity using proliferating cell nuclear antigen, DNA flow cytometry, and p53.
Oshiro Y; Fukuda T; Tsuneyoshi M
Am J Surg Pathol; 1994 Jul; 18(7):712-9. PubMed ID: 7517104
[TBL] [Abstract][Full Text] [Related]
19. p53 overexpression in human esophageal carcinoma: a correlation with tumor DNA ploidy and two parameter flow cytometric study.
Goukon Y; Sasano H; Nishihira T; Nagura H; Mori S
Anticancer Res; 1994; 14(3B):1305-12. PubMed ID: 7915093
[TBL] [Abstract][Full Text] [Related]
20. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
